Bora Lim

7.5k total citations · 2 hit papers
153 papers, 3.8k citations indexed

About

Bora Lim is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Bora Lim has authored 153 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 65 papers in Cancer Research and 42 papers in Molecular Biology. Recurrent topics in Bora Lim's work include Breast Cancer Treatment Studies (42 papers), HER2/EGFR in Cancer Research (41 papers) and Cancer Genomics and Diagnostics (22 papers). Bora Lim is often cited by papers focused on Breast Cancer Treatment Studies (42 papers), HER2/EGFR in Cancer Research (41 papers) and Cancer Genomics and Diagnostics (22 papers). Bora Lim collaborates with scholars based in United States, South Korea and Japan. Bora Lim's co-authors include Naoto T. Ueno, Wendy A. Woodward, Puneet Singh, James M. Reuben, Xiaoping Wang, Nicholas E. Navin, Yiyun Lin, Gabriel N. Hortobágyi, Eric Jonasch and Daniel J. McGrail and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.

In The Last Decade

Bora Lim

136 papers receiving 3.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

2021 672 citations Bora Lim, Naoto T. Ueno et al. Annals of Oncology profile →
Targeting Apoptosis in Cancer

2022 148 citations Bora Lim et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Bora Lim	1.9k	1.3k	1.3k	793	565	153	3.8k
Ying Yang	1.7k 0.9×	1.3k 0.9×	2.2k 1.6×	868 1.1×	502 0.9×	136	5.1k
Saranya Chumsri	2.1k 1.1×	1.0k 0.8×	1.3k 1.0×	588 0.7×	628 1.1×	125	3.8k
Timothy R. Wilson	2.2k 1.1×	961 0.7×	2.3k 1.8×	1.1k 1.4×	327 0.6×	88	4.3k
Robert R. Langley	1.9k 1.0×	908 0.7×	2.0k 1.5×	1.0k 1.3×	664 1.2×	66	4.5k
Shakeel Modak	1.5k 0.8×	869 0.6×	1.7k 1.2×	827 1.0×	758 1.3×	160	4.7k
Deborah Dillon	1.5k 0.8×	829 0.6×	1.5k 1.1×	473 0.6×	361 0.6×	87	3.7k
Yue Zhao	1.2k 0.6×	1.4k 1.0×	1.9k 1.5×	780 1.0×	510 0.9×	140	4.0k
Wei Guo	1.2k 0.6×	1.1k 0.8×	2.3k 1.7×	824 1.0×	488 0.9×	174	4.2k
Eddy S. Yang	1.7k 0.9×	624 0.5×	2.2k 1.6×	667 0.8×	350 0.6×	167	4.4k
Rafael López‐López	2.2k 1.1×	1.7k 1.3×	1.8k 1.4×	934 1.2×	250 0.4×	242	4.5k

Countries citing papers authored by Bora Lim

Since Specialization

Citations

This map shows the geographic impact of Bora Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bora Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bora Lim more than expected).

Fields of papers citing papers by Bora Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bora Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bora Lim. The network helps show where Bora Lim may publish in the future.

Co-authorship network of co-authors of Bora Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Bora Lim. A scholar is included among the top collaborators of Bora Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bora Lim. Bora Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jaehnig, Eric J., Meenakshi Anurag, Jonathan T. Lei, et al.. (2025). NF1-depleted ER ⁺ breast cancers are differentially sensitive to CDK4/6 inhibitors. Science Translational Medicine. 17(813). eadq5492–eadq5492.

Lim, Bora, Stephanie J. Bouley, James A. Walker, et al.. (2025). Development of a Novel Biomarker Platform for Profiling Key Protein–Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs. Cancers. 17(11). 1852–1852. 1 indexed citations

Morita, Daisuke, Amanda Rosewell Shaw, Greyson Biegert, et al.. (2024). Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. Journal for ImmunoTherapy of Cancer. 12(12). e009741–e009741. 1 indexed citations

Huang, Monica L., Deanna L. Lane, Rosalind P. Candelaria, et al.. (2024). Defining Breast Cryoablation Treatment Success: A Guide for the Curative and Palliative Treatment of Breast Cancer. Academic Radiology. 31(12). 4759–4771. 1 indexed citations

Mazumder, Aloran, Jonathan T. Lei, Bora Lim, et al.. (2023). Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness. Science Advances. 9(26). eadf2860–eadf2860. 10 indexed citations

Chen, Natalie, Daniel Wang, Caroline E. Porter, et al.. (2023). Abstract P3-06-04: Treatment of Metastatic Breast Cancer with Multipotent Oncolytic/Helper Adenovirus CAdVEC. Cancer Research. 83(5_Supplement). P3–6. 2 indexed citations

Lim, Bora, David A. Potter, Mohamad A. Salkeni, et al.. (2021). Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3329–3338. 12 indexed citations

Postlewait, Lauren M., Mediget Teshome, Carolyn Hall, et al.. (2021). The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of Surgical Oncology. 28(8). 4265–4274. 18 indexed citations

Fernández, José Rodrigo Espinosa, James P. Long, Toshiaki Iwase, et al.. (2021). Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS ONE. 16(4). e0250057–e0250057. 7 indexed citations

10.

Kida, Kumiko, Kenneth R. Hess, Bora Lim, et al.. (2020). Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers. 12(11). 3105–3105. 1 indexed citations

11.

Postlewait, Lauren M., Mediget Teshome, Sarah M. DeSnyder, et al.. (2020). Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Annals of Surgical Oncology. 27(12). 4603–4612. 12 indexed citations

12.

Lim, Bora, Juhee Song, Nuhad K. Ibrahim, et al.. (2020). A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. The Oncologist. 26(2). e230–e240. 5 indexed citations

13.

Ding, Qingqing, Hui Chen, Bora Lim, et al.. (2019). HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Human Pathology. 92. 32–38. 12 indexed citations

14.

Lee, Jangsoon, Takahiro Kogawa, Peter Ordentlich, et al.. (2017). Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clinical Cancer Research. 23(16). 4780–4792. 40 indexed citations

15.

Ralff, Marie D., C. Leah B. Kline, Jessica Wagner, et al.. (2017). ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Molecular Cancer Therapeutics. 16(7). 1290–1298. 38 indexed citations

16.

Kono, Miho, Takeo Fujii, Bora Lim, et al.. (2017). Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer. JAMA Oncology. 3(9). 1266–1266. 167 indexed citations

17.

Fujii, T., Takahiro Kogawa, Wanli Dong, et al.. (2017). Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology. 28(10). 2420–2428. 110 indexed citations

18.

Allen, Joshua E., Varun V. Prabhu, Mala K. Talekar, et al.. (2015). Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Research. 75(8). 1668–1674. 35 indexed citations

19.

Hao, Sijie, Shuwen Wang, Yuanjun Zhao, et al.. (2015). A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. Molecular Cancer Therapeutics. 14(3). 835–843. 18 indexed citations

20.

Lee, Hee Jin, In Hye Song, An Na Seo, et al.. (2014). Correlations Between Molecular Subtypes and Pathologic Response Patterns of Breast Cancers After Neoadjuvant Chemotherapy. Annals of Surgical Oncology. 22(2). 392–400. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact